SOURCE: Kalorama Information

June 25, 2008 10:23 ET

Kalorama Sees Growth of SNP Analysis Market Following Passage of GINA

NEW YORK, NY--(Marketwire - June 25, 2008) - The recent passage of the Genetic Information Nondisclosure Act (GINA) should alleviate privacy concerns surrounding the use of genetic testing, and open up the market for technologies such as SNP analysis, according to a new report from Kalorama Information, SNP Genotyping Markets and Analysis.

SNPs (single nucleotide polymorhpisms), which are variations at a single site in DNA, have become appealing for several reasons -- they are numerous, stable, easy to score and account for 80-90% of genetic variation, which makes them ideal for the task of hunting for correlations between genotype and phenotype. That means SNP analysis could indicate the likelihood of a disease in a patient or the effectiveness of a drug therapy and thus could have useful applications in pharmacogenomics, pharmacogenetics, and clinical testing.

Mainly carried out in core labs, SNP analysis has been adopted in most of the same places as sequencing and PCR, with a slightly different focus, probably due to the higher costs typically involved, as well as the different advantages. The emphasis of most research has been on finding near-term uses for SNPs in diagnostics, biotechnology and drug development as opposed to pursuing basic research questions.

"The most significant barrier to the future of SNPs, or any genetic analysis, is the concern for privacy," said Bruce Carlson, Publisher of Kalorama Information. "Costs of technology will tend to go down over time, but if patients are afraid to get tested because they think it will affect them down the line, that would stunt growth. GINA, once signed into law, could go a long way towards reducing concerns."

Kalorama expects demand for SNP analysis to be strong, due to the many applications with proven value in the life sciences. Revenues of $625 million in 2007 are expected to grow by a solid double-digit annual growth rate to over $2.2 billion by 2013. The bulk of this revenue will be consumables, with software and instruments making up the remainder.

Kalorama Information's report SNP Genotyping Markets and Analysis details the latest trends, developments, challenges, and applications in this rapidly expanding area of genetics. The report can be purchased directly from Kalorama Information by visiting

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. Kalorama routinely assists media with healthcare topics, and can provide experts to speak about markets in the life sciences industry.

Contact Information